Nxera Pharma and Shionogi partner on Quviviq

1 October 2024

Nxera Pharma (TYO: 4565) has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi (TYO: 4507) regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan.

At the same time, the previous commercialization arrangement between Nxera and Mochida Pharmaceutical (TYO: 4534) has been terminated. After negotiation between Shionogi and Mochida, Shionogi will be solely responsible for distribution and sales activities in Japan.

Quviviq is a novel dual orexin receptor antagonist, discovered by Swiss firm Idorsia (SIX: IDIA), that was approved by Japan’s Ministry of Health, Labor and Welfare of Japan (MHLW) for the treatment of adult patients with insomnia last month.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK